Cargando…

Safety of SARS-CoV-2 mRNA vaccines and effects of immunosuppressive drugs on adverse reactions in patients with rheumatic diseases

Detalles Bibliográficos
Autores principales:	Kawazoe, Mai, Nishio, Junko, Hirose, Wataru, Furukawa, Karin, Nanki, Toshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Federation of Internal Medicine. Published by Elsevier B.V. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272941/ https://www.ncbi.nlm.nih.gov/pubmed/37339924 http://dx.doi.org/10.1016/j.ejim.2023.06.014

Ejemplares similares

Influence of immunosuppressive therapy on longitudinal changes in anti-SARS-CoV-2 spike protein antibodies after two doses of mRNA vaccines in patients with rheumatic diseases
por: Kawazoe, Mai, et al.
Publicado: (2023)

Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases
por: Kaneko, Kaichi, et al.
Publicado: (2022)

Methotrexate-associated lymphoproliferative disorders in the central nervous system and stomach: A case report
por: Kawazoe, Mai, et al.
Publicado: (2020)

Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists
por: Kawazoe, Mai, et al.
Publicado: (2021)

Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial
por: Nanki, Toshihiro, et al.
Publicado: (2022)

Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents
por: Kamei, Koichi, et al.
Publicado: (2022)

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
por: Muraoka, Sei, et al.
Publicado: (2021)

Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2022)

Senescence of alveolar epithelial cells impacts initiation and chronic phases of murine fibrosing interstitial lung disease
por: Yamada, Zento, et al.
Publicado: (2022)

Corrigendum: Senescence of alveolar epithelial cells impacts initiation and chronic phases of murine fibrosing interstitial lung disease
por: Yamada, Zento, et al.
Publicado: (2023)

Rheumatic Immuno-related Adverse Events following Immunotherapy with Checkpoint Inhibitors: Adverse Drug Reaction, or Other?
por: Manzo, Ciro
Publicado: (2021)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Vaccination Against SARS-CoV-2 in Immunosuppressed Patients with Rheumatic Diseases: Position Statement of the Greek Rheumatology Society
Publicado: (2020)

COVID-19 in rheumatic disease patients on immunosuppressive agents
por: Sharmeen, Saika, et al.
Publicado: (2020)

Immunogenicity and safety of routine vaccines in children and adolescents with rheumatic diseases on immunosuppressive treatment — a systematic review
por: Keller, Michèle, et al.
Publicado: (2021)

SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy
por: Lledó, Ana, et al.
Publicado: (2021)

Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination
por: Frey, Sarah, et al.
Publicado: (2021)

Association of Systemic Adverse Reactions and Serum SARS-CoV-2 Spike Protein Antibody Levels after Administration of BNT162b2 mRNA COVID-19 Vaccine
por: Takahashi, Wataru, et al.
Publicado: (2022)

Is it safe to vaccinate rheumatic immunosuppressed patients? Yes, of course, but how?
por: Gillet, Pierre
Publicado: (2021)

Adverse cutaneous reactions after mRNA SARS-CoV-2 vaccination in 3 patients: a spectrum of severity
por: Edgerley, Sarah, et al.
Publicado: (2022)

Humoral immune response to SARS-CoV-2 mRNA vaccines is associated with choice of vaccine and systemic adverse reactions
por: Klingel, Hanna, et al.
Publicado: (2023)

Diagnostic performance of measuring antibodies to the glycopeptidolipid core antigen specific to Mycobacterium avium complex in patients with rheumatoid arthritis: results from a cross-sectional observational study
por: Hirose, Wataru, et al.
Publicado: (2015)

Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy
por: Sugihara, Koichi, et al.
Publicado: (2022)

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
por: Geisen, Ulf M, et al.
Publicado: (2021)

Neurological Adverse Reactions to SARS-CoV-2 Vaccines
por: Finsterer, Josef
Publicado: (2023)

Safety of SARS-CoV-2 Vaccination in Patients with Vascular Malformations: Patient-Reported Adverse Vaccine Reactions
por: Shiraishi, Makoto, et al.
Publicado: (2023)

Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID-19 Global Rheumatology Alliance physician-reported registry
por: Kihara, Mari, et al.
Publicado: (2022)

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence
por: Venerito, Vincenzo, et al.
Publicado: (2020)

Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease
por: Connolly, Caoilfhionn M, et al.
Publicado: (2022)

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2021)

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines
por: Bellinato, Francesco, et al.
Publicado: (2021)

A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases
por: Tzioufas, Athanasios G., et al.
Publicado: (2021)

Retrospective study on the effects of immunosuppressive therapy in uveitis associated with rheumatic diseases in Korea
por: Lee, Sang Yeob, et al.
Publicado: (2011)

Immediate reactions after mRNA SARS-CoV-2 vaccination
por: Jeimy, Samira, et al.
Publicado: (2021)

Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
por: Sieiro Santos, Cristiana, et al.
Publicado: (2022)

Safety and reported adverse effects of coronavirus disease-2019 (COVID-19) vaccines in patients with rheumatic diseases
por: Aboud, Fatma M., et al.
Publicado: (2023)

Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations
por: Favalli, Andrea, et al.
Publicado: (2022)

Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort
por: Zamani, Batool, et al.
Publicado: (2023)

Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study
por: Rotondo, Cinzia, et al.
Publicado: (2021)

SEROLOGICAL STUDIES IN RHEUMATIC FEVER : I. THE "PHASE" REACTION AND THE DETECTION OF AUTOANTIBODIES IN THE RHEUMATIC STATE
por: Fischel, Edward E., et al.
Publicado: (1949)

Cannot write session to /tmp/vufind_sessions/sess_pp9sgg58bc4kdund4dr8eguc13